Pfizer continues realigning with 3 new units
TRENTON, N.J. — Pfizer Inc. told employees worldwide Tuesday it is replacing its current geographic divisions with new ones focused on primary care, specialty care and operations in emerging markets.
The new units, which will begin operating at the beginning of next year, will have complete responsibility for functions including strategic planning, sales and marketing, and even drug development process — testing experimental compounds in people and tinkering with them to come up with the best dose.
Research operations, including identifying potential compounds and testing in the laboratory and in animals, will remain independent, said Pfizer spokesman Ray Kerins.
Pfizer employs 1,100 at a research facility in Chesterfield.
Last week, Pfizer confirmed that it was making changes in its research operations as it shifted its focus to diseases that have high potential for big profits and for treatment improvements, such as cancer and Alz?heimer’s disease direct faxless payday loans. The impact from that set of changes on the operations in Chesterfield had yet to be determined, Pfizer said.
The changes announced Tuesday are aimed at enabling the company to respond better to the needs of doctors, patients and government and other payers, while increasing innovation and holding the independent business units accountable for meeting targets, Kerins said.
"We believe this is where the company can best unlock the value for customers," he said.